Becton Dickinson and Company (BDX)vsPro-Dex Inc (PDEX)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
PDEX
Pro-Dex Inc
$48.61
-2.76%
HEALTHCARE · Cap: $156.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 30307% more annual revenue ($21.92B vs $72.10M). PDEX leads profitability with a 15.7% profit margin vs 8.0%. PDEX trades at a lower P/E of 14.1x. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
PDEX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Margin of Safety
+44.0%
Fair Value
$67.93
Current Price
$48.61
$19.32 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Every $100 of equity generates 31 in profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : PDEX
The strongest argument for PDEX centers on Return on Equity, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 15.7% and operating margin at 17.5%. Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : PDEX
The primary concerns for PDEX are Market Cap.
Key Dynamics to Monitor
BDX profiles as a value stock while PDEX is a mature play — different risk/reward profiles.
BDX carries more volatility with a beta of 0.31 — expect wider price swings.
PDEX is growing revenue faster at 11.1% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 53/100). PDEX offers better value entry with a 44.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Pro-Dex Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?